News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The company also announced a deal to provide in-house testing services to drugmaker Biotest, as well as changes to its management team.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
The PCR-based test can simultaneously detect for the Zika virus, all serotypes of the dengue virus, the chikungunya virus, the West Nile virus, and a host gene.
The company announced this week the sale of 9,090,909 shares of common stock, which it expects will raise proceeds of roughly $30 million before expenses.
The iC-System is based on on iCubate's amplicon-rescued multiplex PCR technology, which detects multiple pathogens simultaneously.
